Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC

Arndt Vogel· @ArndtVogel · X·2026-10-24 21:23· 16 小时前评分70

正文 · 原文

Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC
#ESMO26 #ESMOAmbassadors
👉ORR: 25% vs 50%, DCR: 75 vs 90%
👉 no new safety signals
🧐Supports the combination with CTx
@myESMO @ASCO

224 浏览 · 3 赞 · 3 转发 · 0 回复

会议摘要

788RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上

Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial

https://esmocongress.esmo.org

NCT06578559NCT06578559按 - **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC 对上

- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

https://esmocongress.esmo.org

NCT06640166NCT06640166按 - **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. 对上

- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

https://esmocongress.esmo.org

来源：Arndt Vogel · x.com